生物制剂在儿童感染SARS-CoV-2后多系统炎症综合征的应用研究进展

Recent research on the application of biologics in the treatment of multisystem inflammatory syndrome in children after SARS-CoV-2 infection

摘要:

儿童多系统炎症综合征（multisystem inflammatory syndrome in children，MIS-C）是儿童感染严重急性呼吸综合征冠状病毒2后出现的类似川崎病的过度炎症症状，多发于8~10岁儿童。首选治疗药物是静脉注射免疫球蛋白和糖皮质激素，文献报道危重症患者可选择生物制剂如白细胞介素1受体拮抗剂阿那白滞素、白细胞介素6受体拮抗剂托珠单抗、肿瘤坏死因子α受体拮抗剂英夫利昔单抗等治疗。该文通过阐述上述生物制剂的作用机制，结合案例具体分析生物制剂在治疗儿童感染严重急性呼吸综合征冠状病毒2后出现MIS-C中的安全性和有效性，以期对具有严重症状的MIS-C治疗提供方案。

Abstract:

Multisystem inflammatory syndrome in children(MIS-C)is a type of hyperinflammatory symptoms similar to Kawasaki disease after severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection and is commonly observed in children aged 8-10 years.Primary therapeutic medications for MIS-C are intravenous immunoglobulins and glucocorticoids.It has been reported that biologics,such as IL-1 receptor antagonist anakinra,IL-6 receptor antagonist tocilizumab,and TNF-αreceptor antagonist infliximab,can be used as an option for critically ill patients.This article elaborates on the mechanism of action of the above biologics and discusses the efficacy and safety biologics in the treatment of MIS-C after SARS-CoV-2 infection,in order to provide methods for the treatment of MIS-C with severe symptoms.